An independent negative effect associated with the prescription of OAC was observed for severe frailty (odds ratio, 0.27; 95% CI 0.08–0.94; p = 0.04) and anemia (odds ratio, 0.25; 95% CI 0.07–0.86; p = 0.03); there was also a trend for an association with the higher CHA2DS2-VASc (odds ratio, 1.63; 95% CI 1.00–2.67; p = 0.05), when controlling for albumin level below 35 g/L and HAS-BLED score ≥ 3. The gene discussed is ALB; the disease is anemia.